BioSpace News Archive

An elevating patient pool in the economies of North America, driven by a large geriatric population may fuel the growth of North America emergency medical supplies market over the time period of 2020-2026.

The North America esoteric testing market is expected to record appreciable growth over the ensuing years, on the back of increasing awareness regarding early diagnosis of rare diseases.

The soaring growth pace of the North America gene editing market is rather evident with the invention of a new CRISPR gene editing technology that enables the detection of the Sars-CoV-2 or COVID-19.

Considered as one of the most modern niche verticals of medical device manufacturing sector, the North America healthcare 3D printing market has gained significant prominence in recent years with the advent of innovative technologies.

The North America healthcare information technology market held a valuation of more than 69 billion in 2019 and is projected to surge at a fruitful CAGR of 14.1% between 2020 and 2026.

Study Led by Gene Therapy Program at the University of Pennsylvania Published in Molecular Therapy

Decibel Therapeutics (Nasdaq: DBTX), a clinical-stage biotechnology company dedicated to discovering and developing transformative treatments to restore and improve hearing and balance, announced today that it will present findings from its drug discovery and development programs at the 44th Annual MidWinter Meeting of the Association for Research in Otolaryngology (ARO)

Gemini Therapeutics, Inc. (Nasdaq: GMTX), a clinical stage precision medicine company developing innovative treatments for genetically defined age-related macular degeneration (AMD) and linked ocular disorders, today announced that Jason Meyeburg, Chief Executive Officer of Gemini Therapeutics, is scheduled to participate virtually in the SVB Leerink 10th Annual Global Healthcare Conference

SyBridge Technologies (“SyBridge) a global technological leader in the tooling and mold industry, announced today that its subsidiary Concours Technologies (“Concours”) has completed the acquisition of Active Industrial Solutions, Inc. and Active Industrial Solutions Tennessee, Inc. (collectively “AIS”).

Astellas Pharma Inc. (TSE: 4503) (President and CEO: Kenji Yasukawa, Ph.D., “Astellas”) today announced positive topline results from the Phase 3 pivotal SKYLIGHT 1™ and SKYLIGHT 2™ clinical trials for fezolinetant, an investigational oral, nonhormonal compound being studied for the treatment of moderate to severe vasomotor symptoms (VMS) – i.e., hot flashes associated with menopause.